An Epidemic of Drug Resistance: Tuberculosis in the Twenty-First Century
Overview
Authors
Affiliations
With an estimated two billion people being carriers of latent tuberculosis infection (LTBI), the gains achieved by increasing access to diagnostics and treatment, although substantial, have had a modest impact on the global burden of tuberculosis (TB). At the same time, increased access to treatment has had the unintended consequence that drug-resistant TB (DR-TB) has increased dramatically. Earlier TB control strategies strongly emphasizing medical treatment have failed to address these issues effectively. The current strategy to eliminate TB by 2050 is accompanied by a call for a paradigm shift, emphasizing patient rights and equity more. Based on ethnographic fieldwork in Odisha, India, and global-level TB conferences, this paper contrasts the dynamics of global health policy and strategy-making with the lived realities of patients with DR-TB. A more thorough rethinking of the biosocial dynamics that impact the pathogenic disease is required to develop a comprehensive paradigm shift for TB control in the twenty-first century.
Complete genome sequence of Wildflower, an O cluster mycobacteriophage.
Sungu N, Machowski E, Ealand C, Kana B Microbiol Resour Announc. 2024; 13(11):e0090824.
PMID: 39431875 PMC: 11555996. DOI: 10.1128/mra.00908-24.
Transcriptional analysis of human peripheral blood mononuclear cells stimulated by antigen.
Wei J, Guo F, Song Y, Xu K, Lin F, Li K Front Cell Infect Microbiol. 2023; 13:1255905.
PMID: 37818041 PMC: 10561294. DOI: 10.3389/fcimb.2023.1255905.
Eedara B, Fan C, Sinha S, Khadka P, Das S Pharmaceutics. 2023; 15(9).
PMID: 37765321 PMC: 10536221. DOI: 10.3390/pharmaceutics15092354.